Connection

MICHAEL TAYLOR to Middle Aged

This is a "connection" page, showing publications MICHAEL TAYLOR has written about Middle Aged.
Connection Strength

0.176
  1. Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clin Cancer Res. 2015 Aug 15; 21(16):3750-8.
    View in: PubMed
    Score: 0.028
  2. The transcriptional landscape of Shh medulloblastoma. Nat Commun. 2021 03 19; 12(1):1749.
    View in: PubMed
    Score: 0.011
  3. Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Rep Med. 2020 06 23; 1(3).
    View in: PubMed
    Score: 0.010
  4. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. J Neuropathol Exp Neurol. 2020 04 01; 79(4):437-447.
    View in: PubMed
    Score: 0.010
  5. Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. JAMA Netw Open. 2019 04 05; 2(4):e192597.
    View in: PubMed
    Score: 0.009
  6. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun. 2018 12 04; 6(1):134.
    View in: PubMed
    Score: 0.009
  7. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. Neuropathology. 2018 Oct; 38(5):475-483.
    View in: PubMed
    Score: 0.009
  8. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol. 2018 08; 136(2):227-237.
    View in: PubMed
    Score: 0.009
  9. DNA methylation-based classification of central nervous system tumours. Nature. 2018 03 22; 555(7697):469-474.
    View in: PubMed
    Score: 0.009
  10. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. Acta Neuropathol. 2018 04; 135(4):617-634.
    View in: PubMed
    Score: 0.009
  11. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun. 2017 08 04; 8(1):186.
    View in: PubMed
    Score: 0.008
  12. Spatial heterogeneity in medulloblastoma. Nat Genet. 2017 May; 49(5):780-788.
    View in: PubMed
    Score: 0.008
  13. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015 May 11; 27(5):728-43.
    View in: PubMed
    Score: 0.007
  14. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014 Jun 15; 120(12):1830-7.
    View in: PubMed
    Score: 0.007
  15. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013 Dec; 126(6):917-29.
    View in: PubMed
    Score: 0.006
  16. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013 Aug 10; 31(23):2927-35.
    View in: PubMed
    Score: 0.006
  17. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012 Jan 20; 148(1-2):59-71.
    View in: PubMed
    Score: 0.006
  18. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011 Aug 16; 20(2):143-57.
    View in: PubMed
    Score: 0.005
  19. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011 Jul 01; 29(19):2717-23.
    View in: PubMed
    Score: 0.005
  20. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. 2010 Dec 10; 28(35):5188-96.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.